Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
HPV vaccination can prevent cervical cancer. Currently, there are two vaccines focused on this virus and its most dangerous types. Both are effective against HPV 16 and 18,…
The trial revealed a linear correlation between higher tumor burden and anti-PD1 and anti-programmed death ligand (PD-L1) checkpoint inhibitors, explained as the immune system responding to reactivation.
Virtually all cervical cancers are caused by the human papillomavirus (HPV). There are more than 200 HPV subtypes and at least 13 are carcinogenic. Two subtypes, HPV 16…
Multiple clinical trials are currently underway examining the possible synergistic effects of combining chemotherapy with immunotherapies for patients with bladder cancer and other metastases.
